MMCM
PJP icon

Murphy & Mullick Capital Management’s Invesco Pharmaceuticals ETF PJP Stock Holding History

Murphy & Mullick Capital Management’s Portfolio PJP Stock Details PJP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.9K Hold
115
– – 0.01% 453
2025
Q4 		$12K Hold
115
– – 0.01% 459
2025
Q3 		$11K Hold
115
– – 0.01% 458
2025
Q2 		$9.19K Hold
115
– – 0.01% 471
2025
Q1 		$9.96K Hold
115
– – 0.01% 446
2024
Q4 		$9.5K Buy
+115
New +$9.89K 0.01% 445

Other funds holding PJP

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
PAM
Peak Asset Management Louisville, Colorado $567M AUM 16.44% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
CI
Cavalier Investments Alpharetta, Georgia $3.7B AUM 51.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Murphy & Mullick Capital Management's PJP Position: Q1 2026 in Review

Murphy & Mullick Capital Management held its Invesco Pharmaceuticals ETF (PJP) position steady in Q1 2026 at 115 shares worth $11.9K. The position accounts for 0.01% of the portfolio, ranked #453.

Murphy & Mullick Capital Management first reported a position in PJP in Q4 2024 and has held it in 6 quarters since. The position peaked at $12K in Q4 2025. 119 funds tracked by Wall St. Rank hold PJP as of Q1 2026.

  • Murphy & Mullick Capital Management held 115 shares of Invesco Pharmaceuticals ETF worth $11.9K as of Q1 2026.
  • Murphy & Mullick Capital Management left its Invesco Pharmaceuticals ETF share count unchanged in Q1 2026.
  • Invesco Pharmaceuticals ETF made up 0.01% of Murphy & Mullick Capital Management's portfolio in Q1 2026, its #453 holding.
  • Murphy & Mullick Capital Management first reported a position in Invesco Pharmaceuticals ETF in Q4 2024 and has held it in 6 quarters since.
  • Murphy & Mullick Capital Management's Invesco Pharmaceuticals ETF position peaked at $12K in Q4 2025.
  • 119 funds tracked by Wall St. Rank held Invesco Pharmaceuticals ETF as of Q1 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q1 2026, filed 17 Apr 2026.